

# 1 Title: UK and US risk factors for hearing loss in neonatal 2 intensive care unit infants

3 Authors: Sally K Thornton<sup>1,2</sup>; Derek J Hoare<sup>1,2</sup>, Alice M Yates<sup>1</sup>; Karen R Willis<sup>3</sup>; Polly Scutt<sup>1,2</sup>; Padraig T  
4 Kitterick<sup>1,2</sup>; Abhijit Dixit<sup>4</sup>, Dulip S Jayasinghe<sup>5</sup>

5 **Short title:** Risk factors for Hearing Loss

## 6 **Author Affiliation's:**

7 <sup>1</sup> Hearing Sciences, Mental Health and Clinical Neurosciences, School of Medicine, The University of  
8 Nottingham, NG1 5DU, UK

9 <sup>2</sup> NIHR Nottingham Biomedical Research Centre, 113 Ropewalk House, Nottingham NG1 5DU

10 <sup>3</sup> The Children's Audiology, 113 Ropewalk House, Nottingham University Hospitals, Nottingham, NG1  
11 5DU, UK

12 <sup>4</sup> Clinical Genetics, City Hospital Campus, Nottingham University Hospitals, Nottingham, Hucknall Rd,  
13 Nottingham NG5 1PB, UK

14 <sup>5</sup> Neonatal Intensive Care Unit, City Hospital Campus, Nottingham University Hospitals, Nottingham,  
15 Hucknall Rd, Nottingham NG5 1PB, UK

16

17 **Key words:** risk factors, hearing loss, neonatal intensive care, high-risk babies, neonatal indicators,

18 **Corresponding author:** Dr SK Thornton, [sally.thornton@nottingham.ac.uk](mailto:sally.thornton@nottingham.ac.uk); Hearing Sciences, Mental  
19 Health and Clinical Neurosciences, School of Medicine, The University of Nottingham, NG1 5DU, UK

## 20 **Key points**

- 21 • Current risk factors listed in UK guidance were highly specific for congenital hearing loss but  
22 not sensitive meaning cases would be missed. US risk factors were more sensitive for  
23 hearing loss but not very specific indicating false positives would be made in this population.
- 24 • Neonates with hearing loss who would *not* have been identified solely according to US or UK  
25 risk factors were born close to term and had few neonatal indicators identified.

26

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 27 Abstract

28 **Importance** Early detection and intervention of hearing loss may mitigate negative effects on  
29 children's development. Children who were admitted to the neonatal intensive care unit (NICU) as  
30 babies are particularly susceptible to hearing loss and risk factors are vital for surveillance.

31 **Design, Setting and Participants** This single-centre retrospective cohort study included data from  
32 142 inborn infants who had been admitted to the NICU in a tertiary regional referral centre. Data  
33 were recorded for 71 infants with confirmed permanent congenital hearing loss hearing loss. To  
34 determine impact of NICU admission independently of prematurity babies were individually  
35 matched with 71 inborn infants on gestational age, birthweight, and sex.

36 **Main Outcomes and Measures** Neonatal indicators were recorded for all children with permanent  
37 congenital hearing loss. Presence of UK and US risk factors for hearing loss were collected on the  
38 neonatal population with hearing loss and for the matched controls.

39 **Results** A fifth (21%) of babies with hearing loss had one or more UK risk factors whereas most  
40 (86%) had at least one US risk factor. False positives would be evident if US factors were used  
41 whereas the matched controls had no UK risk factors. Ten babies who at birth had no UK or US risk  
42 factors did not have any significant neonatal indicators identified in their records, one was ventilated  
43 for one day and two had a genetic anomaly.

44 **Conclusions and Relevance** Current risk factors for hearing loss we identified for follow-up in this  
45 high-risk group are highly specific for congenital hearing loss. UK risk factors were highly specific for  
46 hearing loss but not sensitive and conversely, US risk factors are sensitive but not specific so false  
47 positives would be recorded. A national study of neonatal indicators could provide the utility to test  
48 which combinations of risk factors provide high sensitivity without losing specificity.

49

50

51

52

53

## 54 1. Introduction

55 With ever advancing medical technology it is important to revisit hearing loss (HL) in neonatal  
56 intensive care unit (NICU) graduates. Incidence and prognosis according to some risk factors will  
57 likely change over time. Conversely, neonatal indicators for HL are important to explore in this high-  
58 risk group, as more than a third of countries do not have a newborn hearing screening programme  
59 (NHSP) [1]

60 To date there are few studies on the association between neonatal indicators and HL in high-risk  
61 populations [2–7]. No NICU studies have compared the risk factors currently in UK and US guidance.  
62 Many studies have a limited sample size, and not all studies have included babies with confirmed  
63 permanent HL. It may also prove to be useful to provide a matched control group on gestational age  
64 and weight as then risk factors can be determined independent of prematurity.

65 HL is one of the most common congenital anomalies, occurring in approximately 1–3 infants per  
66 1,000, and is the fourth leading cause of disability globally [8–10]. There are serious negative  
67 consequences associated with undetected HL such as speech, language and cognitive delays, poor  
68 social adjustment, and academic achievement [11–13]. Physical and psychological morbidities may  
69 also co-exist with HL [14] and more than a quarter of children with HL have additional disabling  
70 conditions [15,16]. An aetiological factor can be identified in 50-60% of HL cases – a genetic cause is  
71 present in 60% of infants with HL, peripartum problems in 21%, and cytomegalovirus (CMV)  
72 infection in 19% [17–21].

73 Neonatal indicators are predictive of HL in newborn infant – where prematurity and admission to  
74 the neonatal department are predictors of HL [22, 23]. The very preterm infants have a high risk of  
75 functional impairment of the brainstem auditory pathway [23]. Prevalence of HL increases with  
76 decreasing gestational age and decreasing birthweight [24]. Neonates born at a lower birth weight  
77 (<750g) showed a higher frequency of HL than other infants because they are more likely to have  
78 developed bronchodysplasia, and additional neurological morbidities [25]. Previous data indicate  
79 that other neonatal factors; e.g; mechanical ventilation [26] oxygen therapy [27] and  
80 hyperbilirubinemia [28] are also associated with HL. Recently there has been interest in co-  
81 morbidities of multiple risk factors for HL [14] and Chant et al., 2022 have shown cumulative doses  
82 of ototoxic medication are associated with increased risk of HL in preterm infants.

83 There is international consensus that early diagnosis and follow-up of HL in children is important for  
84 them to achieve satisfactory language outcomes [13,29,30]

85 Highly successful implementation of automated auditory brainstem response (AABR) hearing  
86 screening has been demonstrated in the NICU setting and there is good evidence that newborn  
87 hearing screening programmes (NHSP) achieve early identification of HL [31]. Many NICU babies  
88 fulfil the at-risk criteria to be referred for additional hearing testing at 7-9 months from the Joint  
89 committee on infant hearing (JCIH in the US) or National Institute for Health and Care Excellence,  
90 (NICE) NHSP guidelines in the UK [32,33]. Neonatal indicators for HL remain important to investigate  
91 in resource rich countries because they could change in-line with introduction of new technologies  
92 on the NICU. Many countries do not have a NHSP and do not have the resources to automatically  
93 refer all premature neonates for hearing screening; 38% of the world's newborns have minimal or  
94 no hearing screening [1].

95 There is a paucity of recent studies of HL in the NICU population, and many have not accounted for  
96 the confounding risk factors of low birth weight and prematurity. None have compared the risk  
97 factors currently in the UK and US guidance.

98 The aim of the present study was to determine the reliability of known risk factors in the prediction  
99 of HL in neonates.

100 **Objectives** 1) To determine the sensitivity and specificity for current UK and US risk factors for  
101 hearing loss in these infants. 2) Describe neonatal indicators for babies who would *not* be targeted  
102 by UK or US risk factors.

103

## 104 2. Materials and Methods

105 This study used data from the Nottingham NICU research database (NEAT) under ethical approval to  
106 analyse routinely collected data (REC project ID: 292263), South Central Berkshire Research Ethics  
107 Committee. The data were accessed for research purposes from September 22<sup>nd</sup> 2022 until March  
108 22<sup>nd</sup> 2023 and members of the NEAT database team had access to information that could identify  
109 individual participants during data collection. The data was pseudonymised after data collection.

### 2.1 Description of HL cases and matched controls:

110 The study population consisted of 14,037 babies born in Nottingham and admitted to the NICU in  
111 Nottingham between March 1<sup>st</sup> 2008 and February 29<sup>th</sup> 2020. The cases constitute 71 babies  
112 admitted to the NICU in this same epoch identified on NHSP and then followed up to confirm  
113 congenital permanent HL. When HL is cited in reference to the data in this study, we are referring to  
114 confirmed permanent congenital HL which includes bilateral HL and unilateral HL. We categorised HL

115 in this study according to BSA guidelines as mild, moderate, severe, or profound where hearing  
116 threshold in dB HL is averaged over the frequencies 0.5, 1, 2, and 4 kHz for the better hearing ear.  
117 We had a range of ages of children (birth dates from March 1<sup>st</sup> 2008 and February 29<sup>th</sup> 2020) and the  
118 degree of HL was taken from their most recent audiological report. The hearing data were taken  
119 from the pure-tone audiogram in the main, but also play and visual reinforcement audiometry  
120 depending on age and stage of development. Unfortunately, the tympanometry data in the  
121 audiological notes were not robust so we are unable to report if the hearing loss was conductive,  
122 sensorineural or mixed.

123 Of the 71 cases of HL, 46 babies had confirmed permanent congenital BHL and 25 had confirmed  
124 congenital permanent UHL. Eight children had mild BHL (20-40 dB HL), 24 had moderate BHL (41-70  
125 dB HL), four had severe BHL (71-95dB HL) and eight had profound BHL >95 dB HL. Fourteen of the  
126 patients with UHL had mild or moderate hearing loss (one mild, 13 moderate) and 10 had severe and  
127 two had profound hearing loss in their affected ear. All infants with HL were matched on gestational  
128 age ( $\pm 1$  week), gestational weight ( $\pm 100$ g), sex, and whether they were on the NICU for  $\leq$  or  $\geq 48$   
129 hours. They were matched with infants who passed NHSP and additionally had no known acquired  
130 HL at the time of data collection. Children were matched on these factors as it is already established  
131 in the literature that gestational age and weight impact risk of hearing loss and we wanted to study  
132 the neonatal indicators independent of the degree of prematurity.

133 We collected the neonatal indicators for HL from routinely recorded data on the neonatal clinical  
134 database Badgernet (Clevermed, Edinburgh) from paper notes and other local clinical databases.  
135 These neonatal indicators included all UK and US risk factors (Table 1).

136 **2.11 Inclusion criteria:** Inborn neonates admitted on the day of birth to Nottingham NICU March  
137 1<sup>st</sup>, 2008- February 29<sup>th</sup>, 2020. The HL cases had to have permanent congenital HL (referred on NHSP  
138 and confirmed with later audiological testing). There was also a requirement that they had their  
139 neonatal indicators input onto Badgernet the neonatal database.

140 **2.12 Exclusion criteria:** Matched control cases were excluded if they were referred on the NHSP or  
141 if they later went on to have an acquired HL (at the time of data collection). Cases were also  
142 excluded if they had their hearing screening out of region.

143 **Table 1. UK and US risk factors for referral**

<b>UK Risk factors for hearing loss in the neonatal period according to NHSP 2022 [33]</b>	<b>US Risk factors for hearing loss in the neonatal period according to JCIH 2019[32]</b>
--	---

<ol style="list-style-type: none"> <li>3. Syndromes associated with hearing loss (including Down’s syndrome)</li> <li>4. Cranio-facial abnormalities, including cleft palate</li> <li>5. Confirmed congenital infection (toxoplasmosis or rubella)</li> <li>6. Been in a special care baby unit (SCBU) or neonatal intensive care unit (NICU) over 48 hours, with no clear response automated otoacoustic emissions (AOAE) test for both ears, but clear response automated auditory brainstem response (AABR) for both ears</li> </ol>	<ol style="list-style-type: none"> <li>7. A history of family members being deaf or hard of hearing with onset in childhood</li> <li>8. Infants who require care in the NICU or special care nursery for more than five days is used as an indicator of illness severity.</li> <li>9. Hyperbilirubinemia</li> <li>10. Aminoglycoside administration of &gt; 5 days</li> <li>11. Perinatal asphyxia, HIE particularly if requiring cooling treatment.</li> <li>12. Extracorporeal membrane oxygenation (ECMO)</li> <li>13. In-utero infections (i.e., herpes, rubella, syphilis, and toxoplasmosis). CMV and Zika also</li> <li>14. All craniofacial conditions and physical conditions associated with hearing loss</li> <li>15. More than 400 syndromes and genetic disorders associated with atypical hearing thresholds Peri/postnatal risk factors             <ul style="list-style-type: none"> <li>• Perinatal and postnatal confirmed bacterial and/or viral meningitis or encephalitis (especially herpes viruses and varicella and hemophilus influenza and pneumococcal meningitis</li> <li>• Head trauma particularly injury to the mastoid and chemotherapy</li> <li>• Family/caregiver concern regarding hearing, speech, language, or development requires attention.</li> </ul> </li> </ol>
---	---

144

## 145 **2.2 Data entry and items**

146 Data entry onto NICU Badgernet database was completed by a member of the NICU medical team. A  
147 confirmed in utero infection includes confirmed viral infections, (CMV, rubella etc). Individual cases  
148 were screened by a Consultant Neonatologist to indicate that these babies had a confirmed viral  
149 infection. Confirmed meningitis was an indication in the notes that the baby had a positive septic  
150 screen and cerebral spinal fluid parameters indicating that they had any type of meningitis (bacterial  
151 or viral). Suspected CMV cases were managed according to local guidelines, no national guidelines  
152 are or were in place at the time of data collection.

153 Early-onset infection included any mention of infection (bacterial or viral) in the first 72 hours  
154 recorded as part of their principal diagnoses. The data on trough/peak serum concentrations of  
155 antibiotics, the number of doses administered and duration it was administered was not routinely  
156 recorded on Badgernet. For this study analyses of ototoxic medication were not possible, and we  
157 only recorded binary data i.e., if they were given one or more doses of an aminoglycoside antibiotic,  
158 usually gentamicin. Total days on the NICU were calculated from subtracting birth date from  
159 discharge date from the NICU. There are several risk factors which are observed in the well-baby  
160 population and are risk factors for HL but are not routinely observed in infants admitted to the NICU;  
161 these included chemotherapy, neurodegenerative disorders and temporal bone skull fracture. There  
162 were no cases recorded of any of these risk factors in either HL cases or matched controls during the  
163 12 years of data from this large tertiary centre.

164 **2.3 Statistical Analyses:** A power calculation was not performed as the sample size was  
165 opportunistic and limited by the number of available HL cases with NICU admission at the  
166 Nottingham University Hospitals. Data were analysed with SPSS version 28.0 (SPSS Inc. Chicago, H.).  
167 A medical statistician independently analysed the data for this study.

168 The data were normally distributed but skewed sufficiently to indicate non-parametric statistical  
169 tests should be used. In the subgroup analyses, neonatal indicators for HL cases were compared with  
170 their own matched controls. The data analysed include the number of UK and US risk factors. The  
171 “At least one UK risk factor (%)” and equivalent US rows are a binary version of the variable, the p-  
172 value comes from a chi-squared test. Binary logistic regression was used to assess whether current  
173 UK and US risk factors are associated with hearing loss in the NICU population. We looked at each  
174 risk factor individually and found the sensitivity, specificity and PPV of each risk factor on its own

175 and identified the relationship between risk factor and HL to give an OR. We used this to determine  
176 whether any of the UK or US risk factors were statistically significantly associated with HL.

### 177 3. Results

178 A total of 14,037 neonates were admitted to the NICU in Nottingham over 12 years. Of those, 6,246  
179 were admitted to the NICU and stayed on the NICU  $\geq 48$  hours.

180 Mean gestational age for all babies (HL cases and controls) was 34.6 weeks and mean birth weight  
181 was 1890 g. Incidence of permanent HL was 0.5% of which n=46 was confirmed permanent  
182 congenital BHL and n=25 confirmed permanent congenital UHL.

183 One-hundred and forty-two neonates were included in these analyses: 71 with permanent  
184 congenital hearing loss and 71 matched case-controls with no HL.

#### 185 3.1 Comparison of UK and US risk factors:

186 UK risk factors for HL were specific but not sensitive for hearing loss. Table 2 indicates that most HL  
187 babies (56/71, 79%) had no UK risk factors and 14% (10/71) had no US risk factors. However, UK risk  
188 factors are specific compared with US risk factors as no controls had any ( $\geq 1$ ) of the UK risk factors,  
189 whereas the majority (66%, 47/71) of controls had at least one US risk factor. Including a stay on the  
190 NICU  $\geq 48$  hours as a UK risk factor, increased sensitivity to 92% for babies with HL but 80% of  
191 matched controls would also be targeted.

192 **TABLE 2. UK and US risk factors for babies with HL:**

	HL cases n =71	Matched controls n =71	p-value
<b>Number of UK risk factors</b>			
0	56 (79%)	71 (100%)	
1	11 (15%)	0 (0%)	
2	4 (6%)	0 (0%)	
At least 1 UK risk factor, n (%)	15 (21%)	0 (0%)	0.000042
<b>Number of US risk factors</b>			



0	10 (14%)	24 (34%)	
1	5 (7%)	3 (4%)	
2	40 (56%)	36 (51%)	
3	13 (18%)	8 (11%)	
4	3 (4%)	0 (0%)	
At least 1 US risk factor, n (%)	61 (86%)	47 (66%)	0.0059

193 Stay on the NICU > 48 hours are not included in the UK risk factors as this is one of the factors that was matched on.

194 Using binary logistic regression there was evidence that the proportions of HL cases/matched

195 controls changed as the number of risk factors increase; this was true for both UK and US risk factors

196 (Cochrane-Armitage test; P=.0001, UK risk factors; P=0.003 US risk factors).

197

198 **Table 3. Current UK and US risk factors for HL – binary logistic regression**

Risk factors	Sensitivity	Specificity	PPV	p-value
<b>Risk factor (UK)</b>				
Cranio-facial anomaly	0.18	1.00	1.00	0.97
Syndrome associated hearing loss	0.07	1.00	1.00	0.98
In-utero infection	0.01	1.00	1.00	0.99
<b>Risk factor (US)</b>				
Cranio-facial anomaly	0.18	1.00	1.00	0.97
Syndrome associated hearing loss	0.07	1.00	1.00	0.98
In-utero infection	0.01	1.00	1.00	0.99
HIE	0.94	0.09	0.51	0.35
Meningitis	0.03	0.99	0.67	0.57
Exchange transfusion	0.01	1.00	1.00	0.99
NICU stay > 5 days	0.79	0.34	0.54	0.093

199 *NICU = neonatal intensive care unit, PPV = positive predictive value. NICU stay > 48 hours has not been*

200 *included as this was one of the criteria the data were matched on (NICU stay ≥ 48 or ≤ 48 hours).*

201 Table 3 indicates that current UK risk factors and many US risk factors had high specificity (and PPV)  
 202 and low sensitivity, excepting HIE and NICU stay >5 days which have high sensitivity and low  
 203 specificity. High PPV results can be interpreted as indicating the accuracy of the statistics and show  
 204 how likely it is a patient with the risk factor has hearing loss.

205 **3.2 Children with HL who have *no* US or UK risk factors**

206 **Table 4**

HL	Degree of SNHL	Gestational age (weeks)	Weight (g)	Days on the NICU	Ventilation days	Aetiology of HL	Genetic testing	Result
BHL	Mild to moderate	37	2580	1	0	unknown	Y	Negative for connexin 26/30
BHL	Profound	36	2950	1	0	genetic	Y	Positive for changes in connexin 26 (Pathogenic variants - GJB2 c.35del + GJB6 deletion)
BHL	Mild to moderate	38	3420	4	1	genetic	Y	Positive for changes in connexin 26 (Pathogenic variants - GJB2 c.35del + GJB2 c.101T>C)
BHL	Moderate	41	2920	1	0	unknown	Y	Normal
BHL	Profound	41	3320	1	0	unknown	N	-
BHL	Moderate to severe	39	2110	4	0	Dilatation of vestibular aqueducts	Y	Normal
UHL	Moderate	37	2140	1	0	unknown	N	-
UHL	Mild	41	4820	1	0	unknown	N	-

UHL	Severe to profound	37	2180	6	0	unknown	Y	Normal microarray normal MRI
UHL	Moderate	37	2910	1	0	Missing data	X	-

207

208 **Table 4** illustrates the data for 10/71 (14%) babies that have a HL who would not have been targeted  
209 for HL follow-up by any of the UK or US risk factors (excluding days on the NICU) if they had not been  
210 referred from NHSP. All these babies were born near term ( $\geq 36$  weeks) weighing  $>2$ kg. Only one  
211 baby was ventilated for one day and they had no other neonatal indicators discernible from patient  
212 records. One baby with UHL was on the NICU  $> 5$ days (would be identified by US risk factor) and two  
213 other babies were admitted for more than 24 hours. Six babies had genetic testing, and two babies  
214 tested positive for changes in connexin 26. In the BHL group, one child with BHL had gross motor  
215 delay and two BHL cases were diagnosed later with autistic spectrum disorder.

216 Intrauterine growth restriction was listed as a principal diagnosis for two babies out the ten who had  
217 no UK/US risk factors (one with UHL and one with BHL). Data for head circumference measurement  
218 was only available for one baby with BHL (34cm), all four babies with UHL had head circumference  
219 measures (31, 37.5, 31 and 32cm). Average head circumferences for matched babies were 30cm  
220 (BHL) and 33cm (UHL).

221 **3.3 Genetics:** For children with UHL there was genetic testing in 50% (12/25) of cases totalling 17  
222 tests in 12 children. Ten tests were normal, four had pathogenic variants and two were variants of  
223 unknown significance (VUS), but none were causally related to deafness. For the babies with BHL  
224 there was genetic testing in 70% (32/46) of children and a total of 69 tests in the 32 children. Fifty-  
225 two (52/62) tests were normal. Four identified pathogenic variants causative of deafness, three  
226 were VUS, and three identified carrier statuses of recessive conditions.

227

## 228 4 Discussion

229 The aim of the present study was to investigate the official UK and US risk factors from the neonatal  
230 database in a large tertiary referral centre. These data are important as risk factors change over time  
231 due to technological advancements on the NICU, furthermore, risk factors are used in countries  
232 where NHSP are not in place for targeting follow-up for children with HL.

233 It has been shown that the probability of HL increases with an increase in the number of risk factors  
234 [34]. Most (86%) of our HL cases had at least one US risk factor and in contrast only 21% of HL cases  
235 had one or more UK risk factors. Many of the individual risk factors we recorded had a high degree  
236 of specificity (and PPV) but low sensitivity. The downside of using US risk factors were that they were  
237 not specific, and many (66%) matched controls had one or more factors, whereas no matched  
238 controls had more than one UK risk factor.

239 The current report is distinct from some other studies on HL in high-risk populations because the  
240 babies in this study have confirmed permanent HL. We provide a matched population for  
241 comparison on birth weight, gestational age, sex, and if they have been admitted to the NICU more  
242 than or less than 48 hours.

243 NICU admission alone confers 10 times increased risk of developing HL compared with the well-baby  
244 population. Based on the birth cohort for 2008-2020, the prevalence of congenital HL in our NICU  
245 population was 0.5%, significantly higher than in the well-baby population [35]. Others have found  
246 similar or greater levels of HL in their NICU population [2,5]. If we consider only babies admitted for  
247 more than 48 hours then the prevalence rises to 1%, which could be a more realistic value since  
248 babies who are well but have suspected sepsis were included in NICU admission data during the data  
249 collection period.

250 **4.1 UK and US risk factors:** There are more very low birth weight infants surviving at the limits of  
251 viability, as new technologies and treatments continue to emerge. This constant evolution of  
252 therapeutic interventions and the characteristics of the NICU population have contributed to the  
253 limitations in using a set of risk factors to predict outcome.

254 Kraft et al., (2014) confirmed that most neonatal indicators currently recommended by the JCIH are  
255 effective at identifying infants at increased risk of HL. They found NICU stay >5 days and exposure to  
256 ototoxic medications are only associated with small gains in the number of infants correctly  
257 identified as at risk of HL. UK risk factors which we found to be significantly different from matched  
258 controls despite being very specific, are not sensitive for HL so solely using these criteria, babies who  
259 go on to develop hearing loss would be missed. However, including time spent on the NICU (>48  
260 hours) increases the number of babies who would be targeted, for follow-up hearing tests, to 92%  
261 (80% controls). Collating these data may provide useful information in countries without  
262 comprehensive screening programmes and help them target referral for high-risk infants. However,  
263 there is a difference between lower income countries in the proportion of HL due to preventable  
264 causes. This is most likely because of the higher incidence of infections, such as cCMV infections as  
265 well as fewer programs to support maternal and child health. It is thought that approximately one

266 third of cases of preventable infant hearing loss in lower income countries have infectious causes  
267 such as rubella and meningitis [8].

#### 268 **4.2 Individual risk factors for hearing loss**

269 The neonatal indicators we recorded which were statistically significantly different between the HL  
270 and the matched control group in our study were craniofacial anomalies, early-onset infection and  
271 syndromes associated with HL. We recorded a higher number of craniofacial abnormalities in our HL  
272 population compared with the matched group - many from cases with UHL. Others have found  
273 similar; Meyer et al. (1999) found craniofacial malformations, familial hearing disorders and  
274 neonatal bacterial infections were significant risk factors, whereas complications of prematurity  
275 were not independent risk factors [37], dysmorphic features, low APGAR scores at 1 minute, sepsis,  
276 meningitis, cerebral bleeding, and cerebral infarction were all associated with HL [38].

#### 277 **Time spent on the NICU**

278 In this study infants spent nearly twice as long on the NICU if they had a HL (23 days versus 14 days  
279 for matched controls). It is likely to be a multi-factor causation where babies receiving the highest  
280 level of care are sickest and are potentially exposed to more pharmaceutical agents, noise, and  
281 respiratory support etc. The idea of accumulation of risk factors has gained merit more recently with  
282 another case-controlled study showing HL may be associated with the combination of neonatal  
283 indicators and pharmaceutical agents accumulated over time [7].

284 It has been shown that controlling for the impact of other risk indicators, NICU length of stay  
285 greater than 5 days and exposure to loop diuretics were not associated with an increased risk of  
286 congenital or delayed onset HL [36]. However, their study was not case controlled, and they didn't  
287 look at different levels of care. NICU length of stay has been identified as a risk factor in other  
288 studies but the utility of using a length of stay greater than 5 days has not [39]. The rationale for  
289 NICU stay >5 days in the 2007 JCIH position statement comes from unpublished data from the  
290 National Perinatal Information Network (NPIN). This NPIN data indicates that half of infants  
291 discharged from NICUs in 2005 were discharged before 5 days, and these infants were significantly  
292 less likely to have identified risk indicators. In the current study most babies with HL spent more  
293 than 5 days on the NICU but this was not statistically greater than matched controls.

294 **HIE:** Fitzgerald et al. (2019) found hearing impairment is common (9.5%) in term infants who have  
295 undergone therapeutic hypothermia for moderate/severe HIE [40]. We were not able to verify  
296 different stages of HIE from the patient records but found no difference in the small number of cases  
297 (n=4) with HL and HIE compared to matched controls who had no HL (n=7).

298 **Bilirubin:** Although hyperbilirubinemia is extremely common among neonates and is usually mild  
299 and transient, historically it has led to bilirubin-induced neurologic damage. Bilirubin-induced  
300 auditory impairment is thought to primarily influence brainstem nuclei and the auditory nerve,  
301 leading to auditory neuropathy spectrum disorder [41]. It is difficult to make a definitive statement  
302 about this link as only four babies with HL (all BHL) had severe unconjugated hyperbilirubinemia, and  
303 only one baby received an exchange transfusion. Notably no babies in the matched control group  
304 had severe unconjugated hyperbilirubinemia.

305 **Neonatal infection:** Congenital HL is associated with *Toxoplasma gondii*, Rubella virus, CMV, herpes  
306 simplex virus and *Treponema pallidum* infections [10]. We recorded few confirmed TORCH  
307 infections. However, we did find that any record of early-onset infection indicated a significant  
308 increase in risk of HL compared to matched controls. Sepsis is a common condition in NICU infants  
309 with poor effect on general outcome and health and a strong association between sepsis and HL has  
310 been documented [38]. Confirmed sepsis could not be reported since we did not have that level of  
311 microbiological data available, for example few C-reactive protein data were recorded in Badgernet  
312 for this dataset. Reporting of cCMV was low in this cohort, it is possible that some of the ten babies  
313 who did not have any UK/US risk factors or genetic anomalies had cCMV. A recent study has shown  
314 that the yield of targeted cCMV screening following newborn hearing screening failure was eight  
315 times higher than the estimated national birth prevalence of cCMV and those babies with clinically  
316 unsuspected cCMV disease had confirmed HL [42]. Future research could investigate if those  
317 children without any neonatal indicators or risk factors for HL have cCMV.

318 Bacterial meningitis is a known cause of HL and is recorded in the list of risk factors for UK and US  
319 committees. Deafness is the commonest serious complication of bacterial meningitis in childhood,  
320 approximately 10% of survivors are left with permanent sensorineural hearing loss [43,44].  
321 Fortunately, in the UK meningitis is an uncommon condition and therefore is not found in many  
322 studies evaluating risk factors. We recorded two cases (3%) of confirmed meningitis in our HL cohort  
323 and one in the control group in 12 years.

324 **Ototoxic drug use:** Aminoglycoside antibiotics are widely used because of their extreme  
325 effectiveness and broad-spectrum specificity toward organisms common in neonatal sepsis. Yet,  
326 there is a risk of HL following transient nephrotoxicity in as many as 20% of adult patients receiving  
327 aminoglycosides for extended periods of time [45]. The literature is conflicting about ototoxic drugs  
328 as a risk factor for HL in NICU graduates. One study found HL was not associated with gentamicin use  
329 [40]. Most (94%) of our HL cases had at least one dose of an aminoglycoside but this was not  
330 significantly different from matched controls (90%). Useful peak and trough levels of

331 aminoglycoside medication and number of days medication were not routinely recorded on our  
332 database. If the low prevalence (0.2%) of the m.1555A>G variant in the UK population [46] is  
333 accurate for our study population, then fewer than one baby in our 12-year HL cohort would have  
334 this variant. Evaluation of point of care testing for the m.1555A>G variant to guide antibiotic  
335 prescribing to avoid aminoglycoside ototoxicity has been recently reported [47].

336 **Genetics:** The frequency of hearing loss-associated gene mutations has been seen to be higher in the  
337 NICU population (3%) and the hearing loss-associated gene mutations in the NICU, suggests this  
338 mutation may interact with perinatal high-risk factors [48].

339 In the group with UHL a third of patients had a pathogenic mutation (not necessarily causative) and  
340 in the group with BHL there were four patients (10%) which have a pathogenic mutation, causative  
341 of HL. Two cases had the most common pathogenic mutation - GJB2 variant autosomal recessive  
342 non-syndromic hearing loss and both these cases would not have been targeted if they had passed  
343 the NHSP. The GJB2 gene is located on the DFNB1 locus (13q11-q12), codes for the connexin 26  
344 protein, it presents in the human cochlea from the 22nd week of embryonic development [49]. One  
345 infant with BHL had Ehlers-Danlos syndrome and one infant with BHL had a 17 Mb loss on  
346 chromosome 18 which is associated with craniofacial anomalies amongst other developmental  
347 abnormalities.

348 National guidelines in the UK recommend but do not mandate genetic testing, chromosomal studies,  
349 and CGH microarray for cases of BHL but only in specific instances for cases of UHL. Genetic testing  
350 should be available for all children with UHL, particularly since UHL can be a red flag for other  
351 multiple congenital anomalies which may not come to light until the children are much older [14].

352 **4.3 Future studies:** A multi-centre study would be required to provide both regional and ethnic  
353 diversity to the study to make the results more generalisable. This would also be important in lower-  
354 income countries as their disease demographic differs significantly. Ideally, efforts to identify such  
355 risk indicators would be improved by increasing integration of data collection efforts at a national  
356 level.

357 **4.4 Limitations:** The principal limitation of the current study was the maximum number of HL cases  
358 which could be identified. Sampling bias may have been an issue since we only selected HL cases  
359 which had been referred from NHSP and then confirmed to have a HL. Babies with UHL or mild BHL  
360 could be missed because of current UK NHSP policy. Nearly half of children with HL experience  
361 deterioration in hearing during childhood [50,51], therefore, follow-up of acquired and progressive  
362 HL would be important to study to find factors which may mitigate against progression or target  
363 children who are susceptible. Since our study was retrospective, we could not collect any data that

364 was not routinely documented. Several risk factors (e.g., blood glucose, creatine, or serum  
365 concentrations of gentamicin) which may be relevant were not included in this study for this reason.  
366 We also could not pre-plan testing of individual neonatal indicators, and we needed to test  
367 significance of multiple factors.

368 **5. CONCLUSIONS:** This study confirms in our population that many risk factors currently  
369 recommended are highly specific for identifying infants at risk of congenital HL but have low  
370 sensitivity. However, sensitivity cannot easily be improved in situations where HL would not be  
371 identified by UK or US risk factors, as no other neonatal indicators were exposed in the group who  
372 had no UK/US risk factors. NHSP is the gold standard for identifying HL in babies and relying solely on  
373 neonatal indicators for referral is an inferior option indicating NHSP needs to be developed in every  
374 country. Undiagnosed congenital CMV and genetic anomalies may play a significant role and needs  
375 further investigation. Data integration with a national health body would be required to clarify or  
376 uncover novel risk factors for congenital HL. Preventative measures (e.g., antenatal steroids) and  
377 investigating clinical biomarkers of infection and neonatal HL would be the next step in paediatric HL  
378 research.

#### 379 **Role of the funding source**

380 Funding of this study was provided by the National Institute for Health and Care Research (NIHR)  
381 Nottingham Biomedical Research Centre (BRC). The funder had no role in the design or conduct of  
382 the study, or production of the manuscript. The views therefore expressed are those of the authors,  
383 and not necessarily those of the NIHR, the NHS, or the Department of Health and Social Care.

#### 384 **Conflict of interest**

385 All authors declare that they have no conflict of interest.

386 **Acknowledgements:** Many thanks to Richard Smith for the NHSP data.

#### 387 **CRedit author statement:**

388 **Sally Thornton, Dulip Jayasinghe, Pdraig Kitterick:** Conceptualization, Methodology.

389 **Sally Thornton, Alice Yates, Abhijit Dixit, Dulip Jayasinghe, Karen Willis:** Investigation.

390 **Polly Scutt, Sally Thornton, Alice Yates, Dulip Jayasinghe:** Validation, Formal Analysis.

391 **Sally Thornton, Dulip Jayasinghe** Data curation, Writing- Original draft preparation:

392 **Dulip Jayasinghe, Derek Hoare, Polly Scutt, Sally Thornton:** Writing- Reviewing and Editing.

393

394

395



396 **REFERENCES**

- 397 1. Neumann K, Mathmann P, Chadha S, Euler HA, White KR. Newborn Hearing Screening  
398 Benefits Children, but Global Disparities Persist. *J Clin Med.* 2022;11: 271.  
399 doi:10.3390/JCM11010271/S1
- 400 2. Robertson CMT, Howarth TM, Bork DLR, Dinu IA. Permanent Bilateral Sensory and Neural  
401 Hearing Loss of Children After Neonatal Intensive Care Because of Extreme Prematurity: A  
402 Thirty-Year Study. *Pediatrics.* 2009;123: e797–e807. doi:10.1542/PEDS.2008-2531
- 403 3. Suzuki N, Suzumura H. Relation between predischarge auditory brainstem responses and  
404 clinical factors in high-risk infants. *Pediatr Int.* 2004;46: 255–263. doi:10.1111/J.1442-  
405 200X.2004.01897.X
- 406 4. Chu K, Elimian A, Barbera J, Ogburn P, Spitzer A, Quirk JG. Antecedents of newborn hearing  
407 loss. *Obstetrics and Gynecology.* 2003;101: 584–588. doi:10.1016/S0029-7844(02)03118-6
- 408 5. Hille ETM, Van Straaten HLM, Verkerk PH, Van Straaten I, Verkerk P, Hille E, et al. Prevalence  
409 and independent risk factors for hearing loss in NICU infants. *Acta Paediatr.* 2007;96: 1155–  
410 1158. doi:10.1111/J.1651-2227.2007.00398.X
- 411 6. Nair V, Janakiraman S, Whittaker S, Quail J, Foster T, Loganathan PK. Permanent childhood  
412 hearing impairment in infants admitted to the neonatal intensive care unit: nested case-  
413 control study. *Eur J Pediatr.* 2021;180: 2083–2089. doi:10.1007/S00431-021-03983-7
- 414 7. Chant K, Bitner-Glindzicz M, Marlow N. Cumulative risk factors contributing to hearing loss in  
415 preterm infants. *ADC Fetal and Neonatal.* 2022; 324–331. doi:10.1136/archdischild-2022-  
416 324331
- 417 8. Newsroom. World Health Organization (WHO). In: *Deafness and Hearing Loss.* 2022.
- 418 9. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control  
419 and Prevention. In: <https://www.cdc.gov/ncbddd/hearingloss/index.html>. Jul 2022.
- 420 10. Korver AMH, Smith RJH, Camp G Van, Schleiss MR, Bitner-Glindzicz MAK, Lustig LR, et al.  
421 Congenital hearing loss HHS Public Access. *Nat Rev Dis Primers.* 2017;3: 16094.  
422 doi:10.1038/nrdp.2016.94
- 423 11. Lieu JEC, Kenna M, Anne S, Davidson L. *Hearing Loss in Children A Review.* 2020.  
424 doi:10.1001/jama.2020.17647
- 425 12. Lieu JEC. *Permanent Unilateral Hearing Loss (UHL) and Childhood Development.* 2018.  
426 doi:10.1007/s40136-018-0185-5
- 427 13. Netten AP, Rieffe C, Theunissen SCPM, Soede W, Dirks E, Korver AMH, et al. Early  
428 identification: Language skills and social functioning in deaf and hard of hearing preschool  
429 children. *Int J Pediatr Otorhinolaryngol.* 2015;79: 2221–2226.  
430 doi:10.1016/J.IJPORL.2015.10.008
- 431 14. Horrocks LM, Kitterick PT, Jayasinghe DS, Willis KR, Martin KRM, Dixit A, et al. Multiple  
432 congenital anomalies and adverse developmental outcomes are associated with neonatal  
433 intensive care admission and unilateral hearing loss. *Front Pediatr.* 2022;10: 1068884.  
434 doi:10.3389/fped.2022.1068884

- 435 15. Holden-Pitt L, Diaz JA. Thirty Years of the Annual Survey of Deaf and Hard-of-Hearing Children  
436 & Youth: A Glance Over the Decades. *Am Ann Deaf*. 1998;143: 71–76.  
437 doi:10.1353/AAD.2012.0630
- 438 16. Holseth K, Mattson TS. Children with congenital hearing loss – a vulnerable group. *Tidsskrift*  
439 *for Den norske legeforening*. 2019;139. doi:10.4045/TIDSSKR.18.0939
- 440 17. Yelverton JC, Dominguez LM, Chapman DA, Wang S, Pandya A, Dodson KM. Risk factors  
441 associated with unilateral hearing loss. *JAMA Otolaryngol Head Neck Surg*. 2013;139: 59–63.  
442 doi:10.1001/jamaoto.2013.1097
- 443 18. Howell JB, Appelbaum EN, Armstrong MF, Chapman D, Dodson KM. An Analysis of Risk  
444 Factors in Unilateral Versus Bilateral Hearing Loss. *Ear Nose Throat J*. 2019;98: 330–333.  
445 doi:10.1177/0145561319840578
- 446 19. Appelbaum EN, Howell JB, Chapman D, Pandya A, Dodson KM. Analysis of risk factors  
447 associated with unilateral hearing loss in children who initially passed newborn hearing  
448 screening. *Int J Pediatr Otorhinolaryngol*. 2018;106: 100–104.  
449 doi:10.1016/j.ijporl.2018.01.024
- 450 20. Niu K, Brandström A, Skenbäck S, Duan M, Uhlén I. Risk factors and etiology of childhood  
451 hearing loss: a cohort review of 296 subjects. *Acta Otolaryngol*. 2020;140: 668–674.  
452 doi:10.1080/00016489.2020.1757753
- 453 21. Hirvonen M, Ojala R, Korhonen P, Haataja P, Eriksson K, Gissler M, et al. Visual and Hearing  
454 Impairments After Preterm Birth. *Pediatrics*. 2018;142. doi:10.1542/PEDS.2017-3888
- 455 22. Meyer C, Witte J, Hildmann A, Hennecke KH, Schunck KU, Maul K, et al. Neonatal Screening  
456 for Hearing Disorders in Infants at Risk: Incidence, Risk Factors, and Follow-up. *Pediatrics*.  
457 1999;104: 900–904. doi:10.1542/PEDS.104.4.900
- 458 23. Wang C, Jiang ZD. Brainstem auditory abnormality in extremely premature babies and the  
459 impact of neonatal bronchopulmonary dysplasia. *Acta Obstet Gynecol Scand*. 2018;97: 545–  
460 551. doi:10.1111/AOGS.13312
- 461 24. van Dommelen P, Verkerk PH, van Straaten HLM, Baerts W, von Weissenbruch M, Duijsters C,  
462 et al. Hearing loss by week of gestation and birth weight in very preterm neonates. *Journal of*  
463 *Pediatrics*. 2015;166: 840-843.e1. doi:10.1016/j.jpeds.2014.12.041
- 464 25. Martínez-Cruz CF, García Alonso-Themann P, Poblano A, Ochoa-López JM. Hearing Loss,  
465 Auditory Neuropathy, and Neurological Co-morbidity in Children with Birthweight <750 g.  
466 *Arch Med Res*. 2012;43: 457–463. doi:10.1016/J.ARCMED.2012.08.007
- 467 26. Khairy MA, Abuelhamed WA, Ahmed RS, el Fouly HES, Elhawary IM. Hearing loss among high-  
468 risk newborns admitted to a tertiary Neonatal Intensive Care Unit. *J Matern Fetal Neonatal*  
469 *Med*. 2018;31: 1756–1761. doi:10.1080/14767058.2017.1326902
- 470 27. Thangavelu K, Martakis K, Fabian S, Venkateswaran M, Roth B, Beutner D, et al. Prevalence  
471 and risk factors for hearing loss in high-risk neonates in Germany. *Acta Paediatr*. 2019;108:  
472 1972–1977. doi:10.1111/APA.14837
- 473 28. Corujo-Santana C, Falcón-González JC, Borkoski-Barreiro SA, Pérez-Plasencia D, Ramos-  
474 Macías Á. The relationship between neonatal hyperbilirubinemia and sensorineural hearing  
475 loss. *Acta Otorrinolaringol Esp*. 2015;66: 326–331. doi:10.1016/J.OTORRI.2014.10.001

- 476 29. June Holstrum W, Gaffney M, Gravel JS, Oyler RF, Ross DS. Early Intervention for Children  
477 With Unilateral and Mild Bilateral Degrees of Hearing Loss. *Trends Amplif.* 2008;12: 35–41.  
478 doi:10.1177/1084713807312172
- 479 30. Ching TYC. Is Early Intervention Effective in Improving Spoken Language Outcomes of  
480 Children With Congenital Hearing Loss? *Am J Audiol.* 2015;24: 345–348.  
481 doi:10.1044/2015\_AJA-15-0007
- 482 31. Davis A, Hind S. The newborn hearing screening programme in England. *Int J Pediatr*  
483 *Otorhinolaryngol.* 2003;67. doi:10.1016/j.ijporl.2003.08.024
- 484 32. The Year 2019 Position Statement was co-authored by the members of the Joint Committee  
485 on Infant Hearing (JCIH). Year 2019 Position Statement: Principles and Guidelines for Early  
486 Hearing Detection and Intervention Programs. *The Journal of Early Hearing Detection and*  
487 *Intervention.* 2019;4: 1–44.
- 488 33. NHSP (2022) Public Health England. [https://www.gov.uk/government/publications/newborn-](https://www.gov.uk/government/publications/newborn-hearing-screening-programme-nhsp-operational-guidance/6-patient-journey-from-screen-to-referral)  
489 [hearing-screening-programme-nhsp-operational-guidance/6-patient-journey-from-screen-to-](https://www.gov.uk/government/publications/newborn-hearing-screening-programme-nhsp-operational-guidance/6-patient-journey-from-screen-to-referral)  
490 [referral.](https://www.gov.uk/government/publications/newborn-hearing-screening-programme-nhsp-operational-guidance/6-patient-journey-from-screen-to-referral) In: *Guidance 6. Patient journey from screen to referral [Internet].* 2022 [cited 31 Jan  
491 2023]. Available: [https://www.gov.uk/guidance/newborn-hearing-screening-programme-](https://www.gov.uk/guidance/newborn-hearing-screening-programme-overview)  
492 [overview](https://www.gov.uk/guidance/newborn-hearing-screening-programme-overview)
- 493 34. Bielecki I, Horbulewicz A, Wolan T. Risk factors associated with hearing loss in infants: an  
494 analysis of 5282 referred neonates. *Int J Pediatr Otorhinolaryngol.* 2011;75: 925–930.  
495 doi:10.1016/J.IJPORL.2011.04.007
- 496 35. Fortnum HM, Summerfield Q, Marshall DH, Davis AC, Bamford JM. Prevalence of permanent  
497 childhood hearing impairment in the United Kingdom and implications for universal neonatal  
498 hearing screening: questionnaire based ascertainment study. doi:10.1136/bmj.323.7312.536
- 499 36. Kraft CT, Malhotra S, Boerst A, Thorne MC. Risk indicators for congenital and delayed-onset  
500 hearing loss. *Otol Neurotol.* 2014;35: 1839–1843. doi:10.1097/MAO.0000000000000615
- 501 37. Coenraad S, Goedegebure A, van Goudoever JB, Hoeve LJ. Risk factors for sensorineural  
502 hearing loss in NICU infants compared to normal hearing NICU controls. *Int J Pediatr*  
503 *Otorhinolaryngol.* 2010;74: 999–1002. doi:10.1016/j.ijporl.2010.05.024
- 504 38. Coenraad S, Goedegebure A, van Goudoever JB, Hoeve LJ. Risk factors for sensorineural  
505 hearing loss in NICU infants compared to normal hearing NICU controls. *Int J Pediatr*  
506 *Otorhinolaryngol.* 2010;74: 999–1002. doi:10.1016/J.IJPORL.2010.05.024
- 507 39. Fortnum H, Davis A. Epidemiology of permanent childhood hearing impairment in Trent  
508 Region, 1985-1993. *Br J Audiol.* 1997;31: 409–446. doi:10.3109/03005364000000037
- 509 40. Fitzgerald MP, Reynolds A, Garvey CM, Norman G, King MD, Hayes BC. Hearing impairment  
510 and hypoxia ischaemic encephalopathy: Incidence and associated factors. *European Journal*  
511 *of Paediatric Neurology.* 2019;23: 81–86. doi:10.1016/j.ejpn.2018.10.002
- 512 41. Olds C, Oghalai JS. Bilirubin-Induced Audiologic Injury in Preterm Infants. *Clin Perinatol.*  
513 2016;43: 313–323. doi:10.1016/J.CLP.2016.01.006
- 514 42. Chung PK, Schornagel F, Oudesluys-Murphy AM, de Vries LS, Soede W, van Zwet E, et al.  
515 Targeted screening for congenital cytomegalovirus infection: clinical, audiological and

- 516 neuroimaging findings. Arch Dis Child Fetal Neonatal Ed. 2022; fetalneonatal-2022-324699.  
517 doi:10.1136/ARCHDISCHILD-2022-324699
- 518 43. Fortnum HM. Hearing impairment after bacterial meningitis: a review. Arch Dis Child.  
519 1992;67: 1128–1133. doi:10.1136/ADC.67.9.1128
- 520 44. Richardson MP, Reid A, Tarlow MJ, Rudd PT. Hearing loss during bacterial meningitis. Arch Dis  
521 Child. 1997;76: 134–138. doi:10.1136/ADC.76.2.134
- 522 45. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol. 2000;5: 3–22.  
523 doi:10.1159/000013861
- 524 46. Göpel W, Berkowski S, Preuss M, Ziegler A, Küster H, Felderhoff-Müser U, et al. Mitochondrial  
525 mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of  
526 preterm infants. BMC Pediatr. 2014;14: 1–5. doi:10.1186/1471-2431-14-210/TABLES/2
- 527 47. McDermott JH, Mahaveer A, James RA, Booth N, Turner M, Harvey KE, et al. Rapid Point-of-  
528 Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care.  
529 JAMA Pediatr. 2022;176: 486. doi:10.1001/JAMAPEDIATRICS.2022.0187
- 530 48. Yang SM, Liu Y, Liu C, Yin AH, Wu YF, Zheng XE, et al. Hearing-loss-associated gene detection  
531 in neonatal intensive care unit. J Matern Fetal Neonatal Med. 2018;31: 284–288.  
532 doi:10.1080/14767058.2017.1282454
- 533 49. Cohn ES, Kelley PM. Clinical Phenotype and Mutations in Connexin 26 (DFNB1/GJB2), the  
534 Most Common Cause of Childhood Hearing Loss. J Med Genet (Semin Med Genet). 1999;89:  
535 130–136. doi:10.1002/(SICI)1096-8628(19990924)89:3
- 536 50. Fitzpatrick EM, Whittingham JA, Durieux-Smith A. Mild bilateral and unilateral hearing loss in  
537 childhood: a 20-year view of hearing characteristics, and audiologic practices before and after  
538 newborn hearing screening. Ear Hear. 2014;35: 10–18. doi:10.1097/AUD.0B013E31829E1ED9
- 539 51. Barreira-Nielsen C, Fitzpatrick E, Hashem S, Whittingham JA, Barrowman N, Aglipay M.  
540 Progressive hearing loss in early childhood. Ear Hear. 2016;37: e311–e321.  
541 doi:10.1097/AUD.0000000000000325
- 542